Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Badalona – page 62

775 clinical trials in Badalona, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Badalona at a glance
775
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

775 trials in Badalona

Open in trial search

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Giredestrant or Tamoxifen for Premenopausal Women with Early ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Parkinson's disease

Not recruiting

Study on BIA 28-6156 for Parkinson's Disease in Patients with GBA1 Gene Variant

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:5,7-Dimethyl-N-((1R,4R)-4-(Pentyloxy)Cyclohexyl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
  • Sponsor:Bial R&D Investments S.A.

Non-small cell lung cancer

Not recruiting

Study Comparing DZD9008 and Chemotherapy for First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Cardiovascular disorder

Not recruiting

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Anal fistula+1

Not recruiting

Study on the Effectiveness and Safety of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells for Treating Complex Perianal Fistulas in Children with Crohn's Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded
  • Sponsor:Takeda Development Center Americas Inc.

COVID-19

Not recruiting

Study on the Effectiveness and Safety of Bemnifosbuvir for High-Risk COVID-19 Patients

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Atea Pharmaceuticals Inc.

Open angle glaucoma+2

Not recruiting

Study on the Effectiveness of Citicoline Eye Drops for Visual Field Preservation in Patients with Open Angle Glaucoma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Citicoline Sodium
  • Sponsor:Omikron Italia S.r.l.

Corneal dystrophy

Not recruiting

Study on the Safety and Effectiveness of Ripasudil Eye Drops for Patients with Fuchs Dystrophy After Cataract Surgery

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ripasudil
  • Sponsor:Kowa Research Institute Inc.

Lung squamous cell carcinoma stage III+1

Not recruiting

Study on the Effect of Ivonescimab, Pemetrexed, and Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation After Previous Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Summit Therapeutics Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Badalona

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for multiple types of cancer such as pancreatic, gastric, and lung cancer. Research emphasizes novel therapeutic approaches and combination treatments.

  • Mantle Cell Lymphoma Studies
  • Advanced NSCLC Treatments
  • Breast Cancer Therapies

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Research focusing on inflammatory and autoimmune disorders, with particular emphasis on new therapeutic approaches for various conditions affecting different body systems.

  • Cutaneous Lupus Erythematosus
  • Plaque Psoriasis
  • Hidradenitis Suppurativa

Trials aim to evaluate novel treatments and improve disease management strategies.

03 Infectious Diseases

Comprehensive studies addressing viral infections and preventive measures, including vaccine development and therapeutic interventions for various infectious diseases.

  • COVID-19 Vaccines
  • HIV Treatment
  • RSV Prevention

Focus on developing effective treatments and preventive strategies for viral infections.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.